Právní předpis byl sestaven k datu 15.06.2025.
Zobrazené znění právního předpisu je účinné od 01.01.2025.
419
XXXXXXXX VLÁDY
ze xxx 11. xxxxxxxx 2024,
xxxxxx xx xxxx xxxxxxxx xxxxx x. 463/2013 Xx., x xxxxxxxxx xxxxxxxxxx látek, ve xxxxx pozdějších předpisů
Vláda xxxxxxxx podle §44c xxxx. 1 x 2 xxxxxx x. 167/1998 Xx., o xxxxxxxxxx xxxxxxx x x xxxxx některých xxxxxxx xxxxxx, xx xxxxx xxxxxx č. 273/2013 Sb. x xxxxxx x. 366/2021 Xx.:
Xx. X
Xxxxxxxx vlády x. 463/2013 Xx., x seznamech xxxxxxxxxx xxxxx, xx xxxxx xxxxxxxx vlády č. 243/2015 Xx., xxxxxxxx xxxxx x. 46/2017 Xx., xxxxxxxx xxxxx x. 30/2018 Sb., xxxxxxxx xxxxx x. 242/2018 Xx., xxxxxxxx xxxxx x. 184/2021 Xx., xxxxxxxx xxxxx x. 159/2022 Sb., xxxxxxxx xxxxx č. 228/2023 Sb., xxxxxxxx xxxxx x. 52/2024 Xx. x nařízení xxxxx x. 176/2024 Xx., se xxxx xxxxx:
1. X xxxxxxx xxxxxxx č. 1 xx xxx xxxxx, xx kterém xx xx xxxxxxx x xxxxxx „Mezinárodní xxxxxxxxxx xxxxx (INN) v xxxxxx xxxxxx“ xxxxxxx xxxxx „Xxxxxxxx“, xxxxxx xxxx řádek, xx xxxxxx xx xx xxxxxxx s xxxxxx „Xxxxxxxxxxx nechráněný název (XXX) v českém xxxxxx“ xxxxxxx xxxxx „Xxxxxxxxxxxx“, ve xxxxxxx x xxxxxx „Chemický xxxxx podle XXXXX“ xx xxxxxxx slovo „xxxxxx 4-(N-(2-methoxyacetyl)anilin)-1-(2-thiofen-2-ylethyl)piperidin-4-karboxylát“ a xx xxxxxxx x xxxxxx „Xxxxxxxx“ jsou xxxxxxx xxxxx „A-3080, Xxxxxxx“.
2. Xxxxxxx x. 3 zní:
„Příloha č. 3
Xxxxxx x. 3 xxxxxxxx látek
|
Mezinárodní nechráněný xxxxx (INN) v českém xxxxxx / xxxxxx xxxxx |
Xxxxx xxxxxxxxxxx nechráněný xxxxx xxxx xxxxx xxxxxx xxxxx |
Xxxxxxxx název xxxxx IUPAC |
Poznámka |
|
Acetylbenzylfentanyl |
benzylacetylfentanyl |
N-fenyl-N-(1-benzyl-piperidin-4-yl)-acetamid |
NSC 73750 |
|
Xxxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]xxxxxxxx |
||
|
Xxxxxxxxxxxxxxxx |
Xxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxx-2-xxxxxx |
|
|
XX-7921 |
3,4-xxxxxxx-X-{[1-(xxxxxxxxxxxxx)xxxxxxxxxx]xxxxxx}xxxxxxxx |
||
|
XX-237 |
xxxxxxxxxx; 1-X-xxxxxxx-4- xxxxxxxxxxxxxxxxxx; |
1-[4-(3-xxxxxxxxx-2-xx-1-xx)xxxxxxxxx-1-xx]xxxxx-1-xx |
|
|
XX-238 |
1-[2,6-xxxxxxxx-4-(3-xxxxxxxxx-2-xxxx)xxxxxxxxx-1-xx]xxxxxx-1-xx |
||
|
Xxxxxxxxxxxxxxxxxxx |
XXX-X; xxxxxxxxxxxx-X |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx-1-2X-1,3-xxxxxxxxxxx-5-xxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxxxx |
X-xxxxx-X-(1-xxxxxx-xxxxxxxxx-4-xx)xxxxxxxx |
||
|
Xxxxxxxxxxxxxxx |
xxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxx |
|
|
Xxxxxxxxxxxxxx |
Xxxxxx-X; X4129 |
X-xxxxx-X-[1 -(xxxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxxxx |
Xxxxxx XxX |
X-(1-xxxxxxxxxxxxxxx-4-xx)-X-xxxxxxxxxx-2-xxxxxxxxxx |
|
|
Xxxxxxxxxx |
X 4793x; U 47931E |
4-brom-N-(2-(dimethylamino) xxxxxxxxxx) xxxxxxxx |
|
|
Xxxxxxx |
Xxxxxxxxx |
3-{1-[1-(4-xxxxxxxxx)xxxxx]xxxxxxxxx-4-xx}-1X-xxxxxxxxxxxx-2-xx |
|
|
Xxxxxxxxxxx |
2-[(4-xxxxxxxxxxx)xxxxxx]-X,X-xxxxxxx-5-xxxxx-xX-xxxxxxxxxxxx-1-xxxxxxxxx |
||
|
4-Xxxxxxxxxxxxxxxxxxxxx |
4-Xx-xXX |
X-(4-xxxxxxxxxx)-2-xxxxxx-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]xxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxx |
xxxxxxxxxxx-X; XX-X |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxxxxxxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxxxxxxxxxxxxxx |
||
|
Xxxxxxxxxxxxxxxx |
X530 |
4-(4-xxxxxxxxxx)-2,2-xxxxxxx-1-(1-xxxxxxxxxxxx)-1-xxxxxxx |
|
|
Xxxxxxxxxx |
4,5α-xxxxx-17-xxxxxxxxxxxxxx-3-xx |
||
|
Xxxxxxxxxxxx-2-xxxxx xxxxxxxx |
X-(2-xxxxxxxxxx)-1-(2-xxxxxxxxxx)xxxxxxxxx-4-xxxx |
||
|
Xxxxxxxxxxxx-4-xxxxx xxxxxxxx |
X-(4-xxxxxxxxxx)-1-(2-xxxxxxxxxx)xxxxxxxxx-4-xxxx |
||
|
Xxxxxxxx |
4,4-xxxxxxx-6-(xxxxxxxxxx-1-xx)xxxxxx-3-xx |
||
|
Xxxxxx |
xxxxxxxxxxxxxx |
2-[2-[(4-xxxxxxxxxxx)xxxxxx]xxxxxxxxxxxx-1-xx]-X,X-xxxxxxxxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxx |
2-{2-[(2,3-xxxxxxx-1-xxxxxxxxxx-5-xx)xxxxxx]-5-xxxxx-1X-xxxxxxxxxxxx-1-xx}-X,X- xxxxxxxxxxxx-1-xxxx |
||
|
Xxxxxxxxxx |
5-xxxxxx xxxxxxxxxxxxx; 5-xxxxxx xxxxxxxxxxxxxxxxxx |
2-[(4-xxxxxxxxxxx)xxxxxx]-X,X-xxxxxxx-5-xxxxxx-1X-xxxxxxxxxxxx-1-xxxxxxxxx |
|
|
Xxxxxxxxxxxxxx |
X-xxxxxxxxxxxxxxxxxxxxx |
2-(4-xxxxxxxxxxxx)-5-xxxxx-1-(2-(xxxxxxxxx-1-xx)xxxxx)-1X-xxxxx[x]xxxxxxxx |
|
|
Xxxxxxxxxxxx |
2-[(4-xxxxxxxxxxx)xxxxxx]-5-xxxxx-1-(2-xxxxxxxxxx-1-xxxxxxx)-1X-xxxxxxxxxxxxx |
||
|
Xxxxxxx |
(5X,6X,7X,14X)-4,5-xxxxx-7-[(2X)-2-xxxxxxxxxxxxx-2-xx]-6-xxxxxxx-17-xxxxxx-6,14-xxxxxxxxxxxxxx-3-xx |
||
|
Xxxxxxxx butanamid xxxxxx |
xxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]-xxxxxxxxx |
|
|
3 -Fenylropanoylfentanyl |
β'-fenylfentanyl |
N-fenyl-N-[1-(2-fenylethyl)piperidin-4-y]-3-fenylpropanamid |
hydrocinnamoylfentanyl |
|
Flunitazen |
N,N-diethyl-2-{2-[(4-fluorfenyl)methyl]-5-nitro-1N-benzimidazol-1-yl}ethanamin |
||
|
2’-Fluor-2-fluor-3-methylfentanyl |
N-(1-(2-fluorfenethyl)-3-methylpiperidin-4-yl)-N-(2-fluorfenyl)propionamid |
||
|
4-Fluor-butyrfentanyl |
4F-BF |
N-(4-fluorfenyl)-N-[(1-(2-fenylethyl)-4-piperidinyl)]butanamid |
|
|
4-Fluor-cyklopropylbenzylfentanyl |
para-fluorcyklopropylbenzyl- fentanyl |
N-(4-fluorfenyl)-N-(1-benzylpiperidin-4-yl)-cyklopropankarboxamid |
|
|
2-Fluorfentanyl |
Ortofluorfentanyl |
N-(2-fluorfenyl)-N-[1-(2-fenylethyl)-4-piperidinyl]propanamid |
2-FF, x-XX |
|
3-Xxxxxxxxxxxxx |
Xxxxxxxxxxxxxxxxx |
X-(3-xxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]xxxxxxxxxx |
3-XX, x-XX |
|
4-Xxxxxxxxxxxxxxxxxxxx |
xxxx-xxxxxxxxxxxxxxxxxxxx; 4X-xxxxxxxxxxxxxxx |
X-(4-xxxxxxxxxx)-X-(1-xxxxxxxxxxxxxxxxx-4-xx)xxxxx-2-xxxxxxxxxx |
|
|
4-Xxxxxxxxxxxxxxxxxxxxx |
4X-1XX |
X-(4-xxxxxxxxxx)-2-xxxxxx-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxxxx]xxxxxxxxxx |
|
|
3-XxxxxxxxxxxxxxxxxXxxxxxxxx |
xxxxx-xxxxxxxxxxxxxxxxxx- xxxxxxxx |
X-(3-xxxxxxxxxx)-2-xxxxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxx |
|
|
2X-xxxxxxx |
2-[xx(xxxxx-2-xx)xxxxx]-1-[1-(2-xxxxxxxxxxx)-1X-xxxxxx-2-xx]xxxxx-1-xx |
||
|
Xxxxxxx XX-17 |
X-[2-(xxxxxxxxxxxxx)xxxxxxxxxx]-X-xxxxx-xxxxx-2-xxxxxxxxxx |
||
|
Xxxxxxxxxxxxxxx |
XX-X; 2-xxxxxxxxxxxxxxxx |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]-xxxxx-2-xxxxxxxxxx |
|
|
(xxx)Xxxxxxx-X-xxxxxxxx X-xxxxxx analog |
N-(1-benzylpiperidin-4-yl)-N-(4-fluorfenyl)butanamid |
||
|
Heroin |
(5R,6S)-4,5-epoxy-17-methylmorfin-7-en-3,6-diyl-diacetát |
||
|
4-hydroxybutyrfentanyl |
4-HO-BF; x-xxxxxxxxxxxxxx xxxxxxxx |
X-(4-xxxxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]-xxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxx |
2-xxxxxx-X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxxx |
||
|
Xxxxxxxxx-X-47700 |
3,4-xxxxxxxX-[2-(xxxxxxxxxxxxx)xxxxxxxxxx]-X-(xxxxxx-2-xx)xxxxxxxx |
||
|
Xxxxxxxxxxxx |
X,X-xxxxxxx-2-[[4-(1-xxxxxxxxxxxx)xxxxx]xxxxxx]-5-xxxxx-1X-xxxxxxxxxxxx-1-xxxxx xxxx |
||
|
Xxxxxxxx-xxxxxxxx |
(4-xxxxxxxxx)-(1-(xxxxxxxxxxxxx)-4-xxxxxxx-4-xxxxxxxxxxxxxxxxxx)xxxxxxxx |
||
|
Xxxxxxxxxxx |
1-[4-(3-xxxxxxx xxxxx)-1 -xxxxxxxxxxxxxxx-4-xx]xxxxxx-1-xx |
||
|
Xxxxxx |
X výjimkou xxxxxx xxx xxxxxxx xxxxxxx xxxxxxx v xxxxxxx x.&xxxx;1 |
||
|
Xxxxxxxxxxxxxxxx |
(2X)-X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]-2-xxxxxxxxx |
||
|
Xxxxxxxxxxxxxxxxxxxxx |
Xxxxxxx-XxX |
2-xxxxxxx-X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxx |
|
|
4-Xxxxxxxxxxxxxxxxxxxx |
4-XxX-XX |
X-(4-xxxxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]xxxxxxxxx |
|
|
2-Xxxxxxxxxxxxxxxxxxxx |
x-xxxxxxxxxxxxxxxxxxxx |
X-(2-xxxxxxxxxxx)-X-[1-(2-xxxxxxxxxx)-xxxxxxxxx-4-xx]-xxxxxxxx |
|
|
2-Xxxxxx-XX-237 |
2-xxxxxx-xxxxxxxxxx |
1-[2-xxxxxx-4-(3-xxxxxxxxx-2-xx-1-xx)xxxxxxxxx-1-xx]xxxxx-1-xx |
|
|
3,4-Xxxxxxxxxxxxx-X-47700 |
3,4-XXX-X-47700; 3,4-XXX-47700; XXX-47; XXX-47700 |
X-(2-(xxxxxxxxxxxxx)xxxxxxxxxx)-X-xxxxxxxxxxx[x][1,3]xxxxxx-5-xxxxxxxxxx |
|
|
α-Xxxxxxxxxxxxxx butanamid xxxxxx |
XX; X-X |
2-xxxxxx-X-xxxxx-X-[1-(1-xxxxxxxxxxx-2-xx)xxxxxxxxx-4-xx]xxxxxxxxxx |
|
|
3 -MethyIkrotonyIfentanyl |
β'-methyIkrotonyIfentanyl |
N-fenyl-A-[1-(2-fenylethyl)-piperidin-4-yl]-3-methylbut-2-enamid |
|
|
Metodesnitazen |
N,N-diethyl-2-[2-[(4-methoxyfenyl)methyl]benzimidazol-1-yl]ethanamin |
||
|
Metonitazen |
N,N-diethyl-2-[2-[(4-methoxyfenyl)methyl]-5-nitrobenzimidazol-1-yl]ethanamin |
||
|
Metonitazepin |
2-(4-methoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzo[d]imidazol |
||
|
MT-45 |
1-cyklohexyl-4-(1,2-difenylethyl)piperazin |
||
|
N-desethyletonitazen |
2-[2-[(4-ethoxyfenyl)methyl]-5-nitro-benzimidazol-1-yl]-N-ethyl-ethanamin |
||
|
N-desethylisotonitazen |
N-ethyl-2-[2-[(4-isopropoxyfenyl)methyl]-5-nitro-benzimidazol-1-yl]ethanamin |
||
|
N-methyl X-47931X |
X-xxxxxxxxxxxxxxxx |
4-xxxx-X-(2-(xxxxxxxxxxxxx)xxxxxxxxxx)-X-xxxxxxxxxxxxxx |
|
|
Xxxxxxxxxx |
xxxxx 2-xxxxxxxxxxx-1-xxxxxxxxxxxxx-3-xx-1-xxxxxxxxxx |
||
|
X-XXXX; xxxxxxxxxxxxxxxxxxxxxxxx |
3-(4-xxxxxx-1-xxxxxxxxxxxxxxx-4-xx)xxxxx acetát |
||
|
OCfentanyl |
A-3217 |
N-(2-fluorfenyl)-2-methoxy-N-[1-(2-fenylethyl)piperidin-4-yl]acetamid |
|
|
Piperidylthiambuten |
piperidinohton, XXX, 127C49 |
1-(4,4-di(thiofen-2-yl)but-3-en-2-yl)piperidin |
|
|
Protonitazen |
N,N-diethyl-5-nitro-2-[(4-propoxyfenyl)methyl]-1-H-benzimidazol-1-ethanamin |
||
|
Protonitazepin |
5-nitro-2-[(4-propoxyphenyl)methyl]-1-(2-pyrrolidin-1-ylethyl)benzimidazole |
||
|
Pryskyřice x&xxxx;xxxxxx |
|||
|
Xxxxxxxxxxxxxxxxxxxxxxx |
XXX-X |
X-(1-xxxxxxxxxxxxxxxxxxx-4-xx)-X-xxxxxxxxxxxxxxxxxxxx-2-xxxxxxxxxx |
|
|
Xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx |
XXXX-xxxxxxxx; XXXX-X |
X-xxxxx-X-[1-(2-xxxxxxxxxx)xxxxxxxxx-4-xx]-2,2,3,3-xxxxxxxxxxxxxxxxxxxxxx-1- karboxamid |
|
|
Thiofenfentanyl |
2-thiofuranyl fentanyl |
N-(1-fenethylpiperidin-4-yl)-N-fenylthiofen-2-karboxamid |
|
|
4-(Trifluormethyl) X-47700 |
X-(2-(xxxxxxxxxxxxx)xxxxxxxxxx)-X-xxxxxx-4-(xxxxxxxxxxxxxx)xxxxxxxx |
||
|
X-47700 |
3,4-xxxxxxx-X-[2-(xxxxxxxxxxxxx)xxxxxxxxxx]-X-xxxxxxxxxxxxxx |
||
|
X-48800 |
2-(2,4-xxxxxxxxxxxx)-X-(2-(xxxxxxxxxxxxx)xxxxxxxxxx)-X-xxxxxxxxxxxxxx |
||
|
X-49900 |
3,4-xxxxxxx-X-[2-(xxxxxxxxxxxx)xxxxxxxxxx]-X-xxxxxxxxxxxxxx |
||
|
X-50488 |
3,4-xxxxxxx-X-xxxxxx-X-[2-(1-xxxxxxxxxxxx)xxxxxxxxxx] xxxxxxxxxxxxxx |
||
|
X-51754 |
2-(3,4-xxxxxxxxxxxx)-X-[2-(xxxxxxxxxxxxx)xxxxxxxxxx]-X-xxxxxxxxxxxxxx |
||
|
XxxxxxXxxxxxxxx |
XXX, XX |
X-xxxxx-X-[1-(2-xxxxxxxxxx)-4-xxxxxxxxx]xxxxxxxxxx; xxxxxxxx xxxxxxxxxx xxxxxx |
Xxxxxx xxxx xxxxxxxx xxxxx xxxxxxxxx x xxxx xxxxxxx xx xxxxx xxxxxxxxx, kdy tyto xxxx xxxxx xxxxxxxxx.“.
3. X xxxxxxx xxxxxxx x. 6 se xxx xxxxx, ve xxxxxx xx xx xxxxxxx s názvem „Xxxxxxxxxxx nechráněný xxxxx (XXX) x xxxxxx xxxxxx“ uvedeno slovo „Xxxxxxxxxxxxx“, xxxxxx xxxx xxxxx, xx kterém xx ve xxxxxxx x xxxxxx „Mezinárodní xxxxxxxxxx xxxxx (INN) x xxxxxx jazyce“ xxxxxxx xxxxx „Gamabutyrolakton“, xx xxxxxxx s xxxxxx „Xxxxx xxxxxxxxxxx xxxxxxxxxx název nebo xxxxx xxxxxx název“ xx uveden xxxx „XXX“, xx sloupci x názvem „Xxxxxxxx xxxxx xxxxx XXXXX“ xx uvedeno slovo „xxxxxx-2-xx“ x xx xxxxxxx x názvem „Xxxxxxxx“ je xxxxxxx xxxxx „gamma-butyrolactone“.
Xx. XX
Xxxxxxxxx xxxxxxx
Xxxx xxxxxxxx xxxx oznámeno x xxxxxxx xx xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) 2015/1535 xx xxx 9. xxxx 2015 x postupu při xxxxxxxxxxx xxxxxxxxx x xxxxxxx technických předpisů x předpisů xxx xxxxxx xxxxxxxxxx xxxxxxxxxxx.
Xx. XXX
Xxxxxxxx
Xxxx nařízení xxxxxx účinnosti dnem 1. ledna 2025, x xxxxxxxx ustanovení čl. I xxxx 3, xxxxx xxxxxx účinnosti xxxx 1. xxxxx 2025.
&xxxx;
Xxxxxxxx vlády:
prof. XxXx. Xxxxx, Xx.X., XX.X., x. r.
Místopředseda xxxxx x xxxxxxx zdravotnictví:
prof. XXXx. Xxxxx, XXx., XXX, XXXX, x. x.
Xxxxxxxxx
Xxxxxx předpis x. 419/2024 Xx. xxxxx xxxxxxxxx dnem 1.1.2025, x xxxxxxxx ustanovení čl. I xxxx 3, xxxxx nabývá xxxxxxxxx 1.4.2025.
Xxxxx xxxxxxxxxxxx právních xxxxx xxxxxx právních xxxxxxxx v xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx jich xxxxxx xxxxxxxxx xxxxx shora xxxxxxxxx xxxxxxxx xxxxxxxx.